This article is more than 5 years old. Information may no longer be current.

CustomCornea granted expansion of treatment range

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

FORT WORTH, Texas — U.S. regulators have expanded the range of treatment for Alcon’s customized wavefront-guided LASIK system, the company announced in a press release.

CustomCornea performed with the Alcon LADARVision system is now approved by the Food and Drug Administration for the treatment of myopia up to –8 D and astigmatism up to –4 D. Initially, the system was approved for correction of myopia up to –7 D and astigmatism up to –0.5 D.

According to Alcon, this expansion gives the CustomCornea “the broadest wavefront-guided treatment range of any refractive laser system in the U.S.”